Early versus delayed intravitreal @entity5935 as an adjuvant in the treatment of presumed XXXX : a randomised trial.

@entity1 @entity2176 @entity1713 @entity5935 @entity532 @entity86 @entity282 @entity5505 @entity3225 @entity1907
AIM: To compare early versus delayed intravitreal @entity5935 as an adjuvant in the treatment of presumed @entity282 after phacoemulsification. METHODS: @entity1 with presumed postcataract surgery @entity3225 were included in this prospective, randomised, multicentre study. On admission, @entity1 received intravitreal @entity2176 and @entity5505 , and were randomly assigned to intravitreal @entity5935 injection (early-IVB) group or no immediate injection (delayed-IVB) group. After 48   h, a second intravitreal antibiotic injection associated with intravitreal @entity5935 was given to all @entity1 . In @entity1 with severe @entity3225 or clinical deterioration, a prompt or delayed vitrectomy was performed. The primary outcome was the proportion of @entity1 achieving a visual acuity (VA) of 20/40 or better at 12   months. The secondary outcomes were the rate of delayed @entity532 ( @entity1713 and @entity1907 ). RESULTS: Ninety-seven eyes of 97 @entity1 were included, 45 in the early-IVB group and 52 in the delayed-IVB group. Overall, 62.9% of @entity1 achieved a VA >= 20/40 at 1   year. There was no statistically significant difference in the visual outcome between the two groups at 1   year, whatever their baseline VA or light perception or hand motion or more (p=0.55 and p=0.10, respectively). The rates of delayed vitrectomy, @entity1713 and @entity1907 bulbi were not significantly different between the two groups (p=0.42, p=0.37 and p=0.44, respectively). CONCLUSIONS: Early intravitreal @entity5935 had no clear advantage versus delayed injection in the management of presumed @entity86 .
